Prognostic Relevance of the Modified Glasgow Prognostic Score in Patients Treated with Enfortumab Vedotin + Pembrolizumab for Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the GUARDIANS Cohort
Background and Objective: Enfortumab vedotin plus pembrolizumab (EV+P) is the first-line standard of care for metastatic urothelial carcinoma (mUC), but outcomes remain heterogeneous despite high response rates. The modified Glasgow Prognostic Score (mGPS), derived from C-reactive protein and albumin, is a prognostic tool across solid tumors but has not been evaluated in patients receiving EV+P. We aimed to determine whether baseline mGPS is independently associated with overall survival (OS) and progression-free survival (PFS) in this population. Methods: We retrospectively analyzed 310 patients treated with first-line EV+P across 19 German centers in the GUARDIANS registry, stratified by baseline mGPS (0: CRP ≤10 mg/L; 1: CRP >10 mg/L, albumin ≥35 g/L; 2: CRP >10 mg/L, albumin <35 g/L). OS and PFS were estimated by Kaplan–Meier methods and compared by log-rank test. Multivariable Cox regression, adjusted for age, ECOG status, and liver metastases, assessed independent prognostic value and discrimination (Harrell’s C-index), which was compared with that of the Bellmunt risk score. Key Findings and Limitations: mGPS was independently associated with both OS and PFS. mGPS 1 and mGPS 2 (vs. mGPS 0) carried hazard ratios of 2.26 (95% CI 1.19–4.29) and 3.11 (95% CI 1.46–6.63) for OS, and 1.63 (95% CI 1.09–2.45) and 2.36 (95% CI 1.43–3.90) for PFS (all p≤0.018; C-index 0.71 and 0.65, respectively). mGPS discriminated similarly to the established Bellmunt risk score (standalone C-index 0.65 vs. 0.66 for OS and 0.62 vs. 0.60 for PFS). ECOG status was also prognostic; liver metastases were not. Limitations include the retrospective design and immature OS follow-up. Conclusions and Clinical Implications: mGPS is a simple, independent, readily available prognostic marker for first-line EV+P that may complement established risk factors for stratification and merits prospective validation.
Authors
- Viktor Grünwald (ORCID: https://orcid.org/0000-0003-2083-7687)
- Nina Holzwarth
- Nadja Strewinsky (ORCID: https://orcid.org/0009-0007-3815-6587)
- Kiriaki Hiller (ORCID: https://orcid.org/0009-0008-9081-9971)
- Thomas Büttner (ORCID: https://orcid.org/0000-0003-0316-9621)
- Eva Erne (ORCID: https://orcid.org/0000-0003-3478-7625)
- Katrin Schlack (ORCID: https://orcid.org/0000-0001-5843-140X)
- Philipp Schmucker (ORCID: https://orcid.org/0000-0002-3487-0560)
- Can Aydoğdu (ORCID: https://orcid.org/0000-0001-9386-0840)
- Frederik Wessels (ORCID: https://orcid.org/0000-0003-4213-8692)
- Severin Rodler (ORCID: https://orcid.org/0000-0002-7600-6535)
- Christopher Darr (ORCID: https://orcid.org/0000-0003-2532-8398)
- Jozefina Casuscelli (ORCID: https://orcid.org/0000-0002-9899-1986)
- Florian Siegel (ORCID: https://orcid.org/0000-0003-3741-3004)
- Pia Paffenholz (ORCID: https://orcid.org/0000-0002-8209-7795)
- Subhajit Mandal (ORCID: https://orcid.org/0000-0002-5578-3634)
- Ludwig O. Pachmayr
- Susan Foller (ORCID: https://orcid.org/0000-0002-8086-9560)
- Niklas Klümper (ORCID: https://orcid.org/0000-0002-3258-0586)
- Johannes Zeyda
- Schnabel Marco
- Muammar Dib
- Louis Rhode
- Stefanie Zschäbitz
- Friedemann Zengerling
- Emily Rinderknecht
- Anna-Lisa Volk
- Martin Hennig
Institutions
- University of Cologne (DE)
- Heidelberg University (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- University Hospital Bonn (DE)
- University Medical Center Freiburg (DE)
- University Hospital Heidelberg (DE)
- LMU Klinikum (DE)
- Düsseldorf University Hospital (DE)
- Universitätsklinikum Tübingen (DE)
- University Hospital Münster (DE)
- Vivantes Klinikum (DE)
- University Hospital Schleswig-Holstein (DE)
- Essen University Hospital (DE)
- Universitätsklinikum Würzburg (DE)
- Jena University Hospital (DE)
- University Hospital Magdeburg (DE)
- University Hospital Cologne (DE)
- University Hospital Ulm (DE)
- University Medical Centre Mannheim (DE)
- University of Regensburg (DE)
- Technical University of Munich (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-20
- DOI
- https://doi.org/10.21203/rs.3.rs-11669920/v1
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- preprint